Improving blood vessel function after trauma to prevent severe lung and organ problems
Official title: Restoring Endothelial Function After Traumatic Injury to Reduce ARDS and Multi-Organ Dysfunction
Funded at University of Colorado Denver · NIH-10920493 · Data updated 2026-11-12
This study is looking at how giving a protein called fibrinogen to trauma patients early on can help their blood vessels heal better, which might prevent serious problems like breathing issues and help them recover faster.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | September 5, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $189,783 |
| NIH project number | 5K23HL165107-02 |
| Project ID | NIH-10920493 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are critically ill trauma patients who are at risk of developing complications like ARDS due to endothelial dysfunction.
✕Less likely to help
Patients who have not experienced trauma or those with pre-existing severe lung or organ conditions may not benefit from this research.
What this research studies
This research investigates how restoring the function of blood vessels can help prevent serious complications like Acute Respiratory Distress Syndrome (ARDS) and multi-organ dysfunction in trauma patients. The approach focuses on using fibrinogen, a protein that helps with blood clotting, to improve the integrity of blood vessel linings after traumatic injuries. By administering fibrinogen early in treatment, the study aims to enhance blood flow and reduce inflammation, potentially leading to better recovery outcomes for critically injured individuals.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of ARDS and improve survival rates for trauma patients.
How similar studies have gone: Previous research has shown promising results with fibrinogen in animal models, but this approach is still being tested in human patients.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Douin, David J. — University of Colorado Denver
- Study coordinator: Douin, David J.
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Lipid-gene Profiles in Septic ARDS
A Mayo Clinic team is studying how dysfunctional HDL in sepsis relates to different ARDS patient outcomes, aiming to find features that could guide better treatment.
-
Improving blood vessel repair after pediatric ARDS
Aims to better repair the lungs of children who have ARDS by delivering targeted therapy to lung blood vessels using tiny nanoparticles.
-
NOX4 links to ARDS risk and progression
Aims to understand how NOX4-driven cell damage may make some adults with ARDS worse off and how this could lead to earlier, targeted care.
-
Leading causes of death in alcoholic ARDS patients using clinical data
This project uses big clinical data and AI to find the main factors that cause death in adults with ARDS who have alcohol use issues, aiming to improve understanding and care.
-
Targeting aging-related blood vessel injury to prevent ARDS in older lungs
Aims to find ways to protect lung blood vessels in older adults to prevent dangerous lung swelling (ARDS).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.